Last Updated : May 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Orgovyx | relugolix | Advanced prostate cancer | Active | |||
| Epkinly | epcoritamab | Relapsed or refractory diffuse large B-cell lymphoma | Active | |||
| Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | Active | |||
| Opdivo | nivolumab | Stage IIB or IIC melanoma, adjuvant | Active | |||
| TBC | talquetamab | Relapsed or refractory multiple myeloma | Active | |||
| Bimzelx | bimekizumab | Ankylosing spondylitis | Active | |||
| Apretude | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active | |||
| Forxiga | Dapagliflozin | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Jinarc | Tolvaptan | Autosomal dominant polycystic kidney disease | Do not list | Complete | ||
| Juxtapid | Lomitapide | Hypercholesterolemia, homozygous familial | Do not list | Complete |
Last Updated : May 18, 2024